Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella Pneumoniae in mice

Respiratory Research

Volumn 13, Issue , 2012, Pages

  Patterson, Craig M ^a   Morrison, Richard L ^a   D'Souza, Alain ^a   Teng, Xu S ^a   Happel, Kyle I ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; CHEMOKINE LIX; FLUTICASONE PROPIONATE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYDROGEN PEROXIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 2; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; FLUTICASONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEREMIA; BACTERIAL CLEARANCE; BACTERIAL PNEUMONIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; HOST RESISTANCE; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LEUKOCYTE MIGRATION; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MALE; MOUSE; NEBULIZATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHAGOCYTOSIS; SURVIVAL; ANIMAL; C57BL MOUSE; CELL CULTURE; INHALATIONAL DRUG ADMINISTRATION; KLEBSIELLA INFECTION; METABOLISM; MICROBIOLOGY; PATHOLOGY;

ADMINISTRATION, INHALATION; ANDROSTADIENES; ANIMALS; CELLS, CULTURED; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICE; MICE, INBRED C57BL; PNEUMONIA, BACTERIAL;

EID: 84861615835     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-13-40     Document Type: Article

References (36)

1. National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma 2007, NIH National Heart, Lung, and Blood Institute, , National Asthma Education and Prevention Program.
2. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176(6):532-555. 10.1164/rccm.200703-456SO, 17507545.
3. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000, 320(7245):1297-1303. 10.1136/bmj.320.7245.1297, 27372, 10807619.
4. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361(9356):449-456. 10.1016/S0140-6736(03)12459-2, 12583942.
5. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 166(8):1084-1091. 10.1164/rccm.2112055, 12379552.
6. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356(8):775-789. 10.1056/NEJMoa063070, 17314337.
7. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007, 176(2):162-166. 10.1164/rccm.200611-1630OC, 17400730.
8. Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008, 102(8):1099-1108. 10.1016/j.rmed.2008.04.019, 18614347.
9. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008, 177(1):19-26.
10. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009, 169(3):219-229. 10.1001/archinternmed.2008.550, 19204211.
11. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009, 34(3):641-647. 10.1183/09031936.00193908, 19443528.
12. Chu HW, Campbell JA, Rino JG, Harbeck RJ, Martin RJ. Inhaled fluticasone propionate reduces concentration of Mycoplasma pneumoniae, inflammation, and bronchial hyperresponsiveness in lungs of mice. J Infect Dis 2004, 189(6):1119-1127. 10.1086/382050, 14999617.
13. Zhou M, Diwu Z, Panchuk-Voloshina N, Haugland RP. A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidases. Anal Biochem 1997, 253(2):162-168. 10.1006/abio.1997.2391, 9367498.
14. Belayat F, Meniai K, Michaux C, Kafidi N, Coignoul F, Dewaele A. In vitro effect of glucocorticoids on phagocytic function of sheep alveolar macrophages. Vet J 1998, 155(2):177-181. 10.1016/S1090-0233(98)80015-4, 9564271.
15. Nakamura Y, Murai T, Ogawa Y. Effect of in vitro and in vivo administration of dexamethasone on rat macrophage functions: comparison between alveolar and peritoneal macrophages. Eur Respir J 1996, 9(2):301-306. 10.1183/09031936.96.09020301, 8777968.
16. Adcock IM, Nasuhara Y, Stevens DA, Barnes PJ. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. Br J Pharmacol 1999, 127(4):1003-1011. 10.1038/sj.bjp.0702613, 1566089, 10433509.
17. Ek A, Larsson K, Siljerud S, Palmberg L. Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Allergy 1999, 54(7):691-699. 10.1034/j.1398-9995.1999.00087.x, 10442524.
18. Blackwood LL, Pennington JE. Dose-dependent effect of glucocorticosteroids on pulmonary defenses in a steroid-resistant host. Am Rev Respir Dis 1982, 126(6):1045-1049.
19. Nash TW, Libby DM, Horwitz MA. Interaction between the legionnaires' disease bacterium (Legionella pneumophila) and human alveolar macrophages. Influence of antibody, lymphokines, and hydrocortisone. J Clin Invest 1984, 74(3):771-782. 10.1172/JCI111493, 425231, 6470140.
20. Nugent KM, Pesanti EL. Chronic glucocorticosteroid therapy impairs staphylococcal clearance from murine lungs. Infect Immun 1982, 38(3):1033-1036. 347853, 7152661.
21. Satoh S, Oishi K, Iwagaki A, et al. Dexamethasone impairs pulmonary defence against Pseudomonas aeruginosa through suppressing iNOS gene expression and peroxynitrite production in mice. Clin Exp Immunol 2001, 126(2):266-273. 10.1046/j.1365-2249.2001.01656.x, 1906189, 11703370.
22. White JC, Lanser ME, Nelson S, Jakab GJ. Methylprednisolone impairs the bactericidal activity of alveolar macrophages. J Surg Res 1985, 39(1):46-52. 10.1016/0022-4804(85)90160-X, 4010275.
23. Barbier M, Agusti A, Alberti S. Fluticasone propionate reduces bacterial airway epithelial invasion. Eur Respir J 2008, 32(5):1283-1288. 10.1183/09031936.00020608, 18684852.
24. Jansen HM, Sachs AP, van Alphen L. Predisposing conditions to bacterial infections in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995, 151(6):2073-2080.
25. Boe DM, Nelson S, Zhang P, Quinton L, Bagby GJ. Alcohol-induced suppression of lung chemokine production and the host defense response to Streptococcus pneumoniae. Alcohol Clin Exp Res 2003, 27(11):1838-1845. 10.1097/01.ALC.0000095634.82310.53, 14634502.
26. Ye P, Rodriguez FH, Kanaly S, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001, 194(4):519-527. 10.1084/jem.194.4.519, 2193502, 11514607.
27. Duong M, Ouellet N, Simard M, Bergeron Y, Olivier M, Bergeron MG. Kinetic study of host defense and inflammatory response to Aspergillus fumigatus in steroid-induced immunosuppressed mice. J Infect Dis 1998, 178(5):1472-1482. 10.1086/314425, 9780270.
28. Rocksen D, Lilliehook B, Larsson R, Johansson T, Bucht A. Differential anti-inflammatory and anti-oxidative effects of dexamethasone and N-acetylcysteine in endotoxin-induced lung inflammation. Clin Exp Immunol 2000, 122(2):249-256. 10.1046/j.1365-2249.2000.01373.x, 1905762, 11091282.
29. Fang FC. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol 2004, 2(10):820-832. 10.1038/nrmicro1004, 15378046.
30. Tsai WC, Strieter RM, Zisman DA, et al. Nitric oxide is required for effective innate immunity against Klebsiella pneumoniae. Infect Immun 1997, 65(5):1870-1875. 175233, 9125574.
31. Skimming JW, Nasiroglu O, Huang CJ, et al. Dexamethasone suppresses iNOS yet induces GTPCH and CAT-2 mRNA expression in rat lungs. Am J Physiol Lung Cell Mol Physiol 2003, 285(2):L484-L491.
32. Matsumura M, Kakishita H, Suzuki M, Banba N, Hattori Y. Dexamethasone suppresses iNOS gene expression by inhibiting NF-kappaB in vascular smooth muscle cells. Life Sci 2001, 69(9):1067-1077. 10.1016/S0024-3205(01)01196-1, 11508649.
33. Kunz D, Walker G, Eberhardt W, Pfeilschifter J. Molecular mechanisms of dexamethasone inhibition of nitric oxide synthase expression in interleukin 1 beta-stimulated mesangial cells: evidence for the involvement of transcriptional and posttranscriptional regulation. Proc Natl Acad Sci U S A 1996, 93(1):255-259. 10.1073/pnas.93.1.255, 40217, 8552616.
34. Lehtimaki L, Kankaanranta H, Saarelainen S, Turjanmaa V, Moilanen E. Inhaled fluticasone decreases bronchial but not alveolar nitric oxide output in asthma. Eur Respir J 2001, 18(4):635-639. 10.1183/09031936.01.00000201, 11716167.
35. Chrousos GP, Harris AG. Hypothalamic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy. 1. General principles. Neuroimmunomodulation 1998, 5(6):277-287. 10.1159/000026348, 9762010.
36. Chrousos GP, Harris AG. Hypothalamic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy. 2. Review of the literature. Neuroimmunomodulation 1998, 5(6):288-308. 10.1159/000026349, 9762011.